TippingPoint Biosciences Secures $4.5M to Target "Undruggable" Epigenetic Interfaces in Pediatric Brain Cancer
Key Insights
TippingPoint Biosciences (search) closed an oversubscribed $4.5 million seed financing led by SOSV (search) and LKS Fund (search) to advance a breakthrough drug discovery platform targeting previously "undruggable" epigenetic protein interfaces (search).
The company's novel approach recreates disease-specific chromatin (search) environments to reveal transient protein-protein interfaces unique to pathological states, addressing limitations of current epigenetic therapies that often disrupt healthy cell functions.
TippingPoint will focus its lead program on Diffuse Intrinsic Pontine Glioma (search) (DIPG (search)), one of the deadliest childhood cancers (search) driven by chromatin (search) biology disruptions.
TippingPoint Biosciences (search) announced the completion of an oversubscribed $4.5 million seed financing round to advance its breakthrough drug discovery platform targeting epigenetic protein interfaces (search) previously considered "undruggable." The financing was led by SOSV (search) and LKS Fund (search), with participation from Sazze Partners, Freeflow Ventures, StoryHouse Ventures, Sontag Innovation Fund, American Cancer (search) Society BrightEdge, XEIA and WeCAN.
The San Francisco-based biotechnology company was co-founded by Laura Hsieh, PhD, and renowned chromatin (search) biologist Geeta Narlikar, PhD, of the University of California, San Francisco (UCSF). Hsieh developed the underlying technology during her postdoctoral research in Narlikar's laboratory, which is widely recognized for tackling challenging mechanistic problems in chromatin biology and genome regulation.
Addressing Critical Limitations in Epigenetic Drug Development
Despite billions of dollars invested over the past decade in therapies targeting epigenetic enzymes, many programs have struggled in clinical trials because drugs that bind catalytic pockets often disrupt essential functions shared by healthy and diseased cells. This represents a critical unmet need in the field.
TippingPoint is pioneering a fundamentally different strategy by recreating disease-specific chromatin (search) environments to reveal transient protein-protein interfaces that are unique to pathological states. This approach unlocks highly selective and previously inaccessible targets within the epigenome (search).
"Many of the most important interactions driving epigenetic disease only exist under very specific biological conditions," said Hsieh, co-founder and CEO of TippingPoint Biosciences (search). "Our technologies precisely recreate those conditions, exposing actionable targets that are currently invisible to traditional drug discovery efforts."
Focus on Deadly Pediatric Brain Cancer
TippingPoint plans to develop and de-risk its epigenetic interface platform by first focusing on Diffuse Intrinsic Pontine Glioma (search) (DIPG (search)), an aggressive pediatric brainstem tumor. DIPG is one of the deadliest childhood cancers (search) and is driven by profound disruptions of chromatin (search) biology, making it a compelling target for the company's approach.
The company previously raised $2.5 million in pre-seed financing, including non-dilutive grants, bringing together foundations and impact investors committed to accelerating therapies for pediatric brain cancer (search), including the Pediatric Brain Tumor Foundation (search) (PBTF (search)) and Yuvaan Tiwari Foundation (search). TippingPoint also received multiple competitive Golden Ticket awards from MBC BioLabs, AbbVie (search), Astellas and ONO Pharmaceuticals (search).
Platform Development and Future Applications
The seed financing will support advancement of TippingPoint's lead program toward proof-of-concept studies in orthotopic DIPG (search) models while expanding the company's epigenetic interface discovery platform. The company aims to unlock broader classes of previously inaccessible targets across cancer (search) and other diseases driven by chromatin (search) dysfunction.
TippingPoint Biosciences (search) represents the first company to develop a screening platform enabling direct targeting of defective chromatin (search) in disease cells without affecting healthy cells. The platform has potential applications across multiple disease areas including cancer (search), neurodegenerative diseases (search) and developmental disorders (search).